Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
May 12, 2022 at 05:10 pm EDT
Share
Ever Supreme Bio Technology Co., Ltd reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was TWD 123.49 million compared to TWD 48.99 million a year ago. Net loss was TWD 9.26 million compared to TWD 13.44 million a year ago. Basic loss per share from continuing operations was TWD 0.1364 compared to TWD 0.2 a year ago. Diluted loss per share from continuing operations was TWD 0.1364 compared to TWD 0.2 a year ago.
Ever Supreme Bio Technology Co., Ltd. is a Taiwan-based company mainly engaged in the research, design, development, manufacture and sales of stem cell products and immune cell products. The Company has three main products. ADCV01 is an autologous dendritic cell tumor vaccine product, which is currently in the phaseII of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product and a new drug for the treatment of myocardial infarction, which is approved by the United States Food and Drug Administration (FDA) clinical phaseI and is currently applying for the phaseI of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product, which is used to treat acute ischemic stroke and is currently in the United States FDA for clinical phase I. The Company plans to develop new products and services including mesenchymal stem cells for the treatment of multiple sclerosis.
EVER SUPREME BIO TECHNOLOGY CO., LTD 
